drugset / Trial / NCT04592653
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study will be conducted in 2 cohorts. A single-center design for the tumor microenvironment (TME) cohort (Cohort 1), and a multicenter design for the less frequent intravenous (IV) dosing cohort (Cohort 2).
Timeline
- Start
- 2020-09-30
- Primary completion
- 2024-07
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemvaleukin Alfa | Protein / enzyme biologic | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |